IN-VITRO AND IN-VIVO STUDIES ON THE DEVELOPMENT OF THE ALPHA-EMITTINGRADIONUCLIDE BISMUTH-212 FOR INTRAPERITONEAL USE AGAINST MICROSCOPIC OVARIAN-CARCINOMA
J. Rotmensch et al., IN-VITRO AND IN-VIVO STUDIES ON THE DEVELOPMENT OF THE ALPHA-EMITTINGRADIONUCLIDE BISMUTH-212 FOR INTRAPERITONEAL USE AGAINST MICROSCOPIC OVARIAN-CARCINOMA, American journal of obstetrics and gynecology, 176(4), 1997, pp. 833-840
OBJECTIVE: Our objective was to develop the alpha-emitting radionuclid
e bismuth 212 for possible intraperitoneal use against microscopic ova
rian cancer. STUDY DESIGN: The radiobiologic effectiveness of bismuth
212 was compared in vitro to x rays and chromic phosphate phosphorus 3
2). The distribution, toxicity, and maximum tolerated dose of bismuth
212 were determined after intraperitoneal administration in animal mod
els. Dose estimates in animals and humans were made. RESULTS: In in vi
tro studies bismuth 212 was three times more effective in eradicating
tumor cells grown in monolayers and in 800 mu m spheroids. In in vivo
studies bismuth 212 was distributed uniformly after intraperitoneal ad
ministration. The maximum tolerated dose in rabbits was 60 mCi. There
was reversible hematologic toxicity with minimal organ damage. Bismuth
212 prolonged survival and cured up to 40% of animals inoculated with
Ehrlich carcinoma cells. Dose estimates made from these studies indic
ated that dosages administered were effective in eradicating tumor cel
ls and were within the radiotolerance of normal human tissue. CONCLUSI
ON: Bismuth 212 appears to be a suitable candidate for intraperitoneal
use against microscopic ovarian cancer.